- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
- Interventions
- mirvetuximab soravtansine (MIRV; IMGN853)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 499
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
- Interventions
- Oral MRT-2359
- Drug
- Lead sponsor
- Monte Rosa Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Rectal Cancer AJCC V8
- Interventions
- Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib
- Biological · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- San Diego, California • Durham, North Carolina
- Conditions
- Melanoma
- Interventions
- In-person counseling, Workbook, Tablet Computer-Based Education
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Standard Adjuvant Endocrine Therapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 162
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
- Conditions
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Interventions
- Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
- Conditions
- Influenza, Vaccination, Risk Reduction, Health Behavior, Health Promotion
- Interventions
- Risk reduction
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51,218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Advanced Solid Tumors
- Interventions
- zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- Riverside, California • Roseville, California • Newark, Delaware + 5 more
- Conditions
- Autism Spectrum Disorder, Behavior, Parenting
- Interventions
- RUBI-A, R-ISLEA
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Jupiter, Florida • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Exercise Training, Aging
- Interventions
- Episodic Future Thinking, Episodic Recent Thinking, Positive Affective Imagery, Neutral Affective Imagery, HIIT Exercise Intervention
- Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- PSA, Elevated PSA, Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 40 Years to 85 Years · Male only
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cocaine Use Disorder
- Interventions
- Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Marburg Hemorrhagic Fever
- Interventions
- AVI-6003, Placebo
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Medication Adherence, Retention in Care
- Interventions
- My Personal Health Guide, My Personal Food Guide
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 34 Years · Male only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bordetella Infections, Bordetella Pertussis Infection, Bordetella Parapertussis Infection
- Interventions
- ARIES Bordetella Assay
- Device
- Lead sponsor
- Luminex Molecular Diagnostics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Grosse Pointe Woods, Michigan • Albuquerque, New Mexico + 2 more
- Conditions
- HER2-positive Breast Cancer, Advanced Breast Cancer
- Interventions
- Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Miami, Florida • Boston, Massachusetts
- Conditions
- Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
- Interventions
- Mindfulness-Based Virtual Reality Intervention
- Other
- Lead sponsor
- Manhattan Psychiatric Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • White Plains, New York
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Mobile, Alabama • Boston, Massachusetts • Houston, Texas
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
- Interventions
- Busulfan, Melphalan, Fludarabine, CD34+ Allogeneic Peripheral Blood Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- Guenther Koehne
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2034
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Breast Cancer, Breast Cancer Female
- Interventions
- Arm A: Radiotherapy Omission, Arm B: Standard Treatment
- Radiation · Other
- Lead sponsor
- Breast Cancer Trials, Australia and New Zealand
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 2
- States / cities
- San Francisco, California • Houston, Texas
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 866 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
- Conditions
- HIV Infections
- Interventions
- Recombinant interleukin-2 (rIL-2)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 78
- States / cities
- Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
- Conditions
- Uveal Melanoma
- Interventions
- IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
- Conditions
- HIV Infections, Sexual Risk Behavior, Substance Use Risks
- Interventions
- Positive Choice
- Behavioral
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 497 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 5
- States / cities
- Oakland, California • San Francisco, California • San Leandro, California